{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:24:22Z","timestamp":1788312262736,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13730-020-00518-1","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T20:05:39Z","timestamp":1597089939000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Expression of aquaporin-2 in the collecting duct and responses to tolvaptan"],"prefix":"10.1007","volume":"10","author":[{"given":"Kota","family":"Kakeshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"518_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/ijms17010105","volume":"17","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K. Urine aquaporin-2: a Promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. Int J Mol Sci. 2016;17:105.","journal-title":"Int J Mol Sci"},{"key":"518_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jjcc.2018.10.003","volume":"73","author":"T Imamura","year":"2019","unstructured":"Imamura T, Kinugawa K. Update of acute and long-term tolvaptan therapy. J Cardiol. 2019;73:102\u20137.","journal-title":"J Cardiol"},{"key":"518_CR3","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240\u20139.","journal-title":"Circ J"},{"key":"518_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease. Circ J. 2013;77:397\u2013404.","journal-title":"Circ J"},{"key":"518_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1172\/JCI103829","volume":"38","author":"NS Bricker","year":"1959","unstructured":"Bricker NS, Dewey RR, Lubowitz H, Stokes J, Kirkensgaard T. Observations on the concentrating and diluting mechanisms of the diseased kidney. J Clin Investig. 1959;38:516\u201323.","journal-title":"J Clin Investig"},{"key":"518_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2016.02.106","volume":"210","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Nakamura T, Sato E, Node K. Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome. Int J Cardiol. 2016;210:1\u20133.","journal-title":"Int J Cardiol"},{"key":"518_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2169\/internalmedicine.56.7539","volume":"56","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Nakamura T, Sato E, Ueda Y, Node K. Different effects of tolvaptan in patients with idiopathic membranous nephropathy with nephrotic syndrome. Intern Med. 2017;56:191\u20136.","journal-title":"Intern Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00518-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-020-00518-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00518-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:13:00Z","timestamp":1628554380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-020-00518-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00518-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Urine aquaporin-2 measurements and immunostaining of aquaporin-2 were approved in the local ethical committee and written informed consents were obtained beforehand from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}